ANI Pharmaceuticals (ANIP) Projected to Post Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) will likely be releasing its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect the company to announce earnings of $2.02 per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:00 AM ET.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $76.70 on Wednesday. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of 47.06 and a beta of 0.50. ANI Pharmaceuticals has a 52-week low of $54.10 and a 52-week high of $99.50. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The stock has a 50 day moving average price of $80.60 and a 200 day moving average price of $86.60.

Insider Buying and Selling

In other news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total transaction of $42,165.00. Following the completion of the sale, the vice president owned 74,374 shares in the company, valued at $6,271,959.42. This represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Krista Davis sold 2,084 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $77.53, for a total transaction of $161,572.52. Following the completion of the transaction, the senior vice president directly owned 50,993 shares in the company, valued at $3,953,487.29. This represents a 3.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 13,459 shares of company stock worth $1,066,611. 12.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Simplex Trading LLC lifted its holdings in ANI Pharmaceuticals by 3,607.1% in the fourth quarter. Simplex Trading LLC now owns 4,152 shares of the specialty pharmaceutical company’s stock valued at $328,000 after acquiring an additional 4,040 shares during the period. Advisory Services Network LLC purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $366,000. Bridgefront Capital LLC purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $372,000. State of Tennessee Department of Treasury lifted its stake in shares of ANI Pharmaceuticals by 54.5% in the second quarter. State of Tennessee Department of Treasury now owns 5,762 shares of the specialty pharmaceutical company’s stock valued at $376,000 after purchasing an additional 2,032 shares during the period. Finally, Graham Capital Management L.P. boosted its holdings in ANI Pharmaceuticals by 57.0% during the fourth quarter. Graham Capital Management L.P. now owns 5,907 shares of the specialty pharmaceutical company’s stock worth $466,000 after buying an additional 2,145 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Key Headlines Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Management will present at three major investor conferences in early March (Raymond James, Leerink Partners, Barclays); live and archived webcasts available on the company site for 90 days — helps visibility and investor access to management’s growth story. GlobeNewswire Release
• Positive Sentiment: Analyst coverage remains constructive: recent buy/overweight ratings and several price targets well above the current price (median/consensus targets indicate upside), supporting investor confidence. MarketBeat Analyst Notes
• Neutral Sentiment: Street preview pieces highlight expected strength in Cortrophin Gel and rare-disease momentum ahead of Q4 results — this implies potential upside but also flags generic pressure risks; outcome depends on reported numbers. Zacks Preview
• Neutral Sentiment: Recorded short-interest data in the feed shows zero shares / anomalous NaN change and a 0.0 days-to-cover metric — appears to be a data glitch and is unlikely to be an actionable signal by itself.
• Neutral Sentiment: Institutional/hedge-fund activity is mixed: some large reallocations reported (both adds and sizable removals across different funds in the latest quarter), so ownership trends are shifting but not uniformly bullish or bearish. Quiver Quant Summary
• Negative Sentiment: Several insiders (including SVP Krista Davis and Head of Rare Disease Christopher Mutz) disclosed market sales of ANIP shares in recent sessions; repeated insider selling can be perceived as a modest negative signal for near-term sentiment. InsiderTrades Filing

Wall Street Analysts Forecast Growth

ANIP has been the topic of a number of recent analyst reports. Barclays assumed coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price on the stock. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Finally, Guggenheim upped their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $103.43.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.